Gemtuzumab Ozogamicin Ozogamicin represents a unique advance in the approach of severe myeloblastic cancer, mainly acute leukemic leukemia (AML). The medication joins a monoclonal immunoglobulin directed against the receptor cell surface protein present on abnormal populations with calicheamicin, resulting in cell-specific killing. Hence, it offers